Results 191 to 200 of about 54,594 (319)

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy. [PDF]

J Biol Eng
Lee J, Han G, Kyung M, Lee S, Kim TW, Jung ST.   +5 more
europepmc   +1 more source

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies [PDF]

Valentina Cardenas Castro, Kevin G. Shim, Mariano Arribas, Justine L. Wilson-Miller, Adrienne Nedved, Jason N. Barreto, Mustaqeem Siddiqui, Joselle Cook, Nadine Abdallah, Rahma Warsame, David Dingli, Wilson I. Gonsalves, Taxiarchis Kourelis, Morie A. Gertz, Suzanne R. Hayman, Nelson Leung, Prashant Kapoor, P. Leif Bergsagel, Udit Yadav, Julia E. Wiedmeier, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Yi Lin, Tyler B. Sandahl, Rafaël Fonseca   +28 more
openalex   +1 more source

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells. [PDF]

Oncoimmunology
Heger L, Kaszubowski T, Amon L, Lehmann CHK, Wingert S, Medina-Echeverz J, Koch J, Hackstein H, Purbojo A, Hartmann A, Alexiou C, Cesnjevar R, Pahl J, Dudziak D.   +13 more
europepmc   +1 more source

Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy

Hong Zhang, Qun Wang, Sireesha Yalavarthi, Lukas Pekar, Steven Shamnoski, Liufang Hu, Laura Helming, Stefan Zielonka, Chunxiao Xu   +8 more
openalex   +1 more source

Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive cohort.
A. Coste, S. Godet, S. Manier, J. R. Eveillard, C. Croizier, C. Mariette, C. Breal, H. Manjra, C. Touzeau, M. Mohty, R. Belkhir, A. Bobin, A. Lévêque, B. Cherel, L. Montes, F. Orsini‐Piocelle, L. Frenzel, D. Robu, E. Chalayer, S. Harel, L. Vincent, L. Bauschert, A. Dony, R. Tabrizi, P. Moreau, C. Hulin, A. Perrot   +26 more
wiley   +1 more source

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]

Front Oncol
Akiyama H, Kakiuchi S, Sakamoto A, Tomigaki N, Fujioka S, Harima I, Niwa R, Takagi I, Kozuki Y, Miyata Y, Yoshihara K, Yoshihara S, Iwata N.   +12 more
europepmc   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source